Tuberculosis (TB) diagnostics are needed to detect exposure, diagnose disease and drug resistance, and to monitor improvement under treatment in both primary healthcare and laboratory settings. The Foundation for Innovative New Diagnostics (FIND) and the Stop TB Partnership’s New Diagnostics Working Group (NDWG) bring to you the latest developments in TB diagnostics R&D. You will hear from leading global experts on the advancements in the TB diagnostics pipeline, improvements in the detection of drug-resistant TB, next-generation sequencing and the diagnosis of TB infection.

**Introduction** by session Chairs
Daniela Maria Cirillo, OSR & NDWG
Nazir Ismail, WHO & NDWG

**Presentations**

- **TB diagnostics pipeline update – 2020 and beyond**
  Morten Ruhwald, FIND & NDWG
  18:20–18:40

- **Recent advances in the diagnosis of drug-resistant TB**
  Adam Penn-Nicholson, FIND
  18:40–18:50

- **Seq&Treat – bringing next-generation TB care to underserved communities**
  Anita Suresh, FIND
  18:50–19:00

- **Improving interpretation of pncA gene mutations for sequencing-based drug susceptibility testing of pyrazinamide**
  Paolo Miotto, OSR & NDWG
  19:00–19:10

- **Advancing the TB prevention agenda**
  Alberto Matteelli, University of Brescia & NDWG
  19:10–19:20

**Closing remarks + Q&A** facilitated by session Chairs
Daniela Maria Cirillo, OSR & NDWG
Nazir Ismail, WHO & NDWG
19:20–19:45

*Participants registered to the conference can attend the session*